Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial results report.
Material Changes
The filing details the company's issued share capital as of February 28, 2013:
- Total Issued Ordinary Shares: 5,401,378,949 (25p each)
- Treasury Shares: 494,951,327
- Total Voting Rights: 4,906,427,622
No comparative data for prior periods is included in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,906,427,622) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (494,951,327) to calculate the free float accurately.
- Review the company's Form 20-F or quarterly earnings releases for financial performance data not contained in this filing.